This article was originally published Dec. 12.
Verinata Health said last week that is has relocated its corporate headquarters and laboratory to a "much larger" facility in Redwood City, Calif.
The move comes as the company prepares to launch in the first quarter of 2012 a next-generation sequencing-based non-invasive prenatal test for multiple chromosomal abnormalities. According to CEO Caren Mason, the new facility demonstrates the firm's "commitment to appropriately prepare for the growth and expansion expected with the launch" of the test.
The new clinical laboratory has an initial capacity of 150,000 tests per year, and the firm's R&D laboratory has been expanded "substantially," according to the company. Space is available for both laboratories to grow further in the future.
Verinata raised about $46.5 million in a Series C financing round this summer. This fall, the company said it has settled on the Illumina HiSeq 2000 as a platform for its test.
Verinata's test is expected to compete with Sequenom's MaterniT21 test for Down syndrome, which Sequenom launched this fall (CSN 10/19/2011), also using the Illumina HiSeq platform. Both firms claim IP rights to the underlying technology (CSN 9/7/2011).